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The insulin/IGF signaling (IIS) pathway is a potent inducer of cell proliferation in normal development
and in cancer. The mechanism by which this occurs, however, is not completely understood. The Hippo
signaling pathway regulates cell proliferation via the transcriptional co-activator Yorkie/YAP, however
the signaling inputs regulating Hippo activity are not fully elucidated. Here we present evidence linking
these two conserved, oncogenic pathways in Drosophila and in mammalian cells. We ﬁnd that
activation of IIS and of Yorkie signaling correlate positively in hepatocellular carcinoma. We show
that IIS activates Yorkie in vivo, and that Yorkie plays an important role in the ability of IIS to drive cell
proliferation. Interestingly, we also ﬁnd the converse—that Yorkie signaling activates components of
the insulin/TOR pathway. In sum, this crosstalk between IIS and Yorkie leads to coordinated regulation
of these two oncogenic pathways.
& 2012 Elsevier Inc. All rights reserved.Introduction
The insulin/IGF signaling (IIS) pathway is a potent driver of
tissue growth in ﬂies and in mammals (Edgar, 2006; Goberdhan
and Wilson, 2003; Mirth and Riddiford, 2007; Nakae et al., 2001;
Wu and Brown, 2006). Both ﬂies and mammals with impaired IIS
display severe growth defects (Bohni et al., 1999; Brogiolo et al.,
2001; Nakae et al., 2001; Rulifson et al., 2002) whereas hyper-
activation of IIS causes tissue overgrowth (Weinkove et al., 1999)
and IIS is frequently hyperactivated in cancer (Bhaskar and Hay,
2007; Bjornsti and Houghton, 2004; Goberdhan and Wilson,
2003; Guertin and Sabatini, 2007).
For a tissue to grow, cells need to both accumulate mass
(‘grow’) and divide (‘proliferate’) in a coordinated fashion. Cell
proliferation without cell growth leads to cells of ever decreasing
size, as occurs during reductive divisions typical of early animal
development. In contrast, cell growth without proliferation leads
to cells of increased size, however this can only occur to a limited
degree. Consequently, only the combination of cell growth and
cell proliferation leads to signiﬁcant tissue growth during normal
development and carcinogenesis. Indeed, IIS is a powerful driver
of tissue growth exactly because it is capable of promoting both
cell growth and cell proliferation (Bohni et al., 1999; Brogiololl rights reserved.
r).et al., 2001; Weinkove et al., 1999). The mechanisms by which IIS
regulates cell proliferation, however, are not well understood.
The fruitﬂy Drosophila has become an important model
organism for understanding mechanisms regulating tissue
growth. In Drosophila, mutations in upstream components of
the insulin pathway, such as Chico (ﬂy insulin receptor substrate),
PTEN and PI3K (Dp110) affect both cell number and cell size
(Bohni et al., 1999; Goberdhan et al., 1999; Leevers et al., 1996),
indicating that they affect both cell growth and cell proliferation.
Flies lacking the downstream factor S6K, however, are small and
have cells of reduced size, but do not have a reduction in cell
number (Montagne et al., 1999). This suggests that the signaling
pathway regulating cell proliferation includes upstream compo-
nents of IIS, but does not include the downstream component
S6K. Recently, reduction of TOR Complex 1 (TORC1) activity was
shown to inhibit cell proliferation via 4E-binding proteins
(4E-BPs) (Dowling et al., 2010), suggesting that part of the ability
of IIS to promote proliferation may be via TORC1. However, in
Drosophila IIS does not activate TORC1 in vivo in most tissues
under normal physiological conditions (Pallares-Cartes et al., 2012;
Radimerski et al., 2002). Furthermore, some tissues such as the
developing Drosophila wing (the wing discs) do not express 4E-BP
(Teleman et al., 2005). These data suggest that IIS may regulate
cell proliferation via TORC1-independent mechanisms. Indeed, in
mammals Akt is known to regulate a number of cell-cycle
regulators such as Myt1, p27kip and p21Cip (Katayama et al.,
2005; Liang et al., 2002; Medema et al., 2000; Okumura et al.,
2002; Rossig et al., 2001; Shin et al., 2002; Viglietto et al., 2002).
However, these mechanisms do not appear to be conserved in
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mechanisms by which IIS regulates cell proliferation, which we
aim to explore here.
The Hippo/Yorkie pathway is a highly conserved, oncogenic
signaling pathway recently discovered in ﬂies, that powerfully
regulates organ size and cell proliferation in ﬂies and in mammals
(Halder and Johnson, 2011; Pan, 2007; Reddy and Irvine, 2008;
Zhao et al., 2010a, b). The effector of the pathway, Yorkie/Yki
(Yes-associated protein (YAP) in mammals), is a transcriptional
co-activator that binds transcription factors such as Scalloped,
thereby driving cell proliferation by inducing expression of genes
that promote the cell cycle (e.g. Cyclin E) or inhibit apoptosis (e.g.
diap1). Yki is inhibited via phosphorylation by a multi-protein
complex composed of two kinases – Hippo (Hpo) and Warts –
each of which is associated with a helper protein, Salvador and
Mats, respectively (Pan, 2007; Zhao et al., 2010a). The upstream
signaling events regulating Hippo activity, however, are not fully
understood. Hpo appears to be a central signaling hub capable of
integrating numerous inputs. Several signaling modules at the cell
membrane were recently identiﬁed as Hpo regulators, including
the expanded/merlin/kibra/crumbs module (Baumgartner et al.,
2010; Feng and Irvine, 2007; Genevet et al., 2010; Grzeschik et al.,
2010; Hamaratoglu et al., 2006; Pellock et al., 2007; Yu
et al.,2010), the fat/four-jointed module (Bennett and Harvey,
2006; Cho et al., 2006; Feng and Irvine, 2007; Silva et al., 2006;
Tyler and Baker, 2007; Willecke et al., 2006) and the Lgl/aPKC
module (Grzeschik et al., 2010; Ling et al., 2010). These compo-
nents relay information regarding cell–cell contacts and apical–
basal polarity to regulate Hpo, although the biochemical mechan-
isms remain to be understood. Whether Hippo signaling is also
responsive to other cellular inputs such as growth factors or
cellular stresses is an open question.
Here, we investigate the relationship between IIS and Hpo/Yki
signaling. We present evidence that Insulin/IGF signaling drives
cell proliferation in part via Hpo/Yki in vivo. We show that
activation of IIS leads to activation of Yki and transcription of
Yki target genes. We show that the activation of Yki is important
for IIS to drive tissue growth in vivo. Finally, we show that this
regulation occurs via PDK1 and Hpo. These ﬁndings provide a
novel mechanism by which insulin signaling promotes prolifera-
tion, and also identify a novel regulatory input into Hippo activity.
Furthermore, we show that activation of Yki leads to activation of
TORC1, suggesting bidirectional, coordinated regulation of the IIS/
TOR and Hippo/Yki pathways. Our data thereby link these two
important oncogenic pathways.Fig. 1. Coordinated activation of the IIS and Yki/YAP signaling pathways in
hepatocellular carcinoma. (A) Activation of the IIS and Yki/YAP pathways corre-
lates positively in HCC. Box plot showing the distribution of nuclear YAP staining
intensity for each level of phosho-Akt. Akt phosphorylation (Ser473) was quanti-
ﬁed on a scale from 0 to 3 and nuclear YAP levels on a scale from 0 to 12 as
described in Materials and Methods for 112 HCC samples. Whiskers represent min
and max of the data, the limits of the box are the 1st and 3rd quartiles, and the
middle line is the median. (Spearman-Rho correlation coefﬁcient¼0.33 and
signiﬁcance¼0.001.) (B–B0) Representative examples of two HCC samples, one
with low levels of nuclear YAP (brown) and Akt phosphorylation (pink) (B), and
one with high levels of both (B0). Nuclei are stained blue with haematoxylin.Results
Coordinated activation of YAP and Akt in hepatocellular carcinoma
The insulin/IGF (IIS) and Yki signaling pathways are both
potent inducers of tissue growth. One could imagine that activa-
tion of only one of these two pathways might be sufﬁcient to
allow tissue growth during carcinogenesis. Alternatively, activa-
tion of these two pathways might be linked. To distinguish
between these two possibilities, we correlated the level of
activation of IIS and Yki/YAP in hepatocellular carcinoma (HCC)
samples. We chose HCC because HCC samples show a broad range
in YAP activation (Zheng et al., 2011), thereby making HCC
suitable for this correlative study. We probed a tissue microarray
containing 112 HCC samples with antibodies detecting phospho-
Akt (Ser473), a commonly used correlate for Akt activation
in cancer (Dai et al., 2005; David et al., 2004; Perez-Tenorio and
Stal, 2002), and antibodies detecting YAP. We quantiﬁed levels
of nuclear YAP since nuclear YAP represents the active fraction.Interestingly, we found a signiﬁcant positive correlation between
levels of phospho-Akt and nuclear YAP (Fig. 1A). Samples with
high Akt phosphorylation tended to also have high levels
of nuclear YAP (Spearman-Rho signiﬁcance score 0.001). This
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signaling might be linked. To study the underlying molecular
mechanisms, we turned to the genetically-tractable Drosophila
system, where the Hpo/Yki pathway was ﬁrst discovered and
described.
PI3K affects Yorkie activity in vivo in Drosophila
We set out to test whether insulin/IGF signaling (IIS) might be
activating Yki and thereby promoting cell proliferation. To this
end, we ﬁrst asked whether PI3K is able to modulate Yki activity
in vivo. We expressed either Dp110-CAAX, a constitutively-active
form of phosphatidylinositol-3-OH kinase (PI(3)K), or Rheb, spe-
ciﬁcally in the wing blade during development using nubbin-
GAL4 (Fig. 2A and A0). Dp110-CAAX causes activation of both
upstream and downstream components of the IIS pathway, while
Rheb is further downstream in the signaling pathway and
activates TOR (Hay and Sonenberg, 2004). The differential actions
of these two components allow us to understand the conse-
quences of activating upstream versus downstream parts of the
IIS pathway. Expression of Dp110-CAAX caused the wing blade to
increase signiﬁcantly in size relative to controls (nt testo0.001,
Fig. 2A and A0, black bars). This increase in total wing size was not
accompanied by a signiﬁcant increase in cell size (Fig. 2A0, grey
bars) indicating that both cell growth and cell proliferation were
proportionally accelerated. The increase in wing size was sig-
niﬁcant but moderate in magnitude (38%), indicating that the
expression conditions we used were within physiological range.
In contrast, expression of Rheb, which acts more downstream in
the IIS pathway and activates TOR, led predominantly to an
increase in cell size (Fig. 2A and A0), indicating TOR has a stronger
effect on cell growth than on cell proliferation. These data are
consistent with previous reports that upstream components of
the pathway such as PI3K, PDK1 and Akt/PKB are mainly respon-
sible for IIS-induced cell proliferation (Bohni et al., 1999;
Goberdhan et al., 1999; Kim et al., 2004; Leevers et al., 1996).
To assay Yki activity under these conditions, we dissected the
developing wing tissue, the wing discs, from third instar larvae
and performed western blot analyses. As expected, expression of
Dp110-CAAX led to activation of both Akt, and the direct TOR
target S6 Kinase (S6K), detected by increased phosphorylation of
these proteins (Fig. 2B). In contrast, expression of Rheb only
caused increased phosphorylation of S6K but not of Akt (Fig. 2B),
consistent with its ability to activate downstream, but not
upstream, components of the insulin pathway. Interestingly,
in vivo expression of Dp110-CAAX led to reduced phosphoryla-
tion of Yki on Ser168 (Fig. 2B), a widely used readout for Yki
activity. Phosphorylation on S168 promotes cytoplasmic reten-
tion and reduced transcriptional activity of Yki (Dong et al., 2007;
Reddy and Irvine, 2008) suggesting that activation of PI3K leads to
increased Yki activity. In contrast, expression of Rheb did not
reduce Yki phosphorylation (Fig. 2B). In sum, these data suggest
that moderate activation of PI3K affects phosphorylation of Yki
in vivo, and that this effect is caused by a component of the IIS
pathway that is upstream of TOR. We also performed the opposite
experiment, testing whether inhibition of endogenous PI3K leads
to increased Yki phosphorylation. Treatment of Drosophila Clone
8 cells, a wing-disc derived cell line, with wortmannin, a speciﬁc
PI3(K) inhibitor, for one hour caused a mild but reproducible
increase in Yki phosphorylation (Fig. 2C).
Since phosphorylation of Yki on Ser168 strongly correlates
with activity, this suggested PI3K affects Yki transcriptional
activity in vivo. To test this, we expressed either constitutively-
active Dp110 (Dp110-CAAX), or dominant-negative Dp110
(Dp110-DN) speciﬁcally in the posterior compartment of the
wing disc using engrailed-GAL4 (Fig. 2E). This allows for directcomparison of the genetically modiﬁed posterior compartment
(P) to the control anterior compartment (A). As a readout for Yki
activity, we employed the widely-used diap-lacZ reporter (Huang
et al., 2005). Expression of Dp110-CAAX caused both an over-
growth of the posterior compartment, as well as an increase in
diap-lacZ reporter expression, compared to the control anterior
compartment (Fig. 2E). Conversely, expression of Dp110-DN,
which reduces endogenous PI3K signaling, caused an under-
growth of the posterior compartment as well as a decrease in
diap-lacZ expression (Fig. 2E), in agreement with our observation
that endogenous levels of PI3K are required to maintain normal
Yki activation. We also measured expression of the three endo-
genous Yki target genes expanded, merlin and cyclin E by
quantitative RT-PCR in discs expressing Dp110-CAAX in the wing
pouch with nubbin-G4, and found them to be signiﬁcantly
elevated compared to control discs (Fig. 2D). Although signiﬁcant,
the magnitude of the effect was moderate, similar in magnitude
to the increase in wing size caused by our Dp110-CAAX expres-
sion conditions (Fig. 2A0). In contrast, expression of Rheb with
nubbin-G4 caused a reduction in expression of Yki targets
(Supplemental Fig. 1). This is consistent with our observation
that PI3K signaling positively regulates Yki activity and that
activation of TOR leads to inhibition of PI3K via a well-established
negative feedback loop (Kockel et al., 2010) (Fig. 7G). In sum,
these data suggest that modulation of PI3K leads to altered Yki
phosphorylation and transcriptional activity, raising the possibi-
lity that part of the proliferation-promoting activity of IIS could be
via Yki.
PI3K affects Yorkie/YAP activity in vivo in mammalian cells
We asked whether PI3K signaling is also able to modulate Yki
phosphorylation in mammalian cells. We treated both mouse
NIH-3T3 ﬁbroblasts and human HeLa cells with wortmannin in
order to block endogenous PI3K signaling, and detected phos-
phorylation of YAP, the mammalian ortholog of Yki. Intriguingly,
phosphorylation of YAP increased in both cell lines in response to
wortmannin (Fig. 3), consistent with our in vivo results in the ﬂy.
Insulin signaling regulates Yorkie activity via PDK1
To study the molecular connection between IIS and Yki
activation, we turned to S2Rþ cells, which harbor functional IIS
and Hpo/Yki signaling pathways. Treatment of S2Rþ cells with
insulin caused a reproducible drop in Yki phosphorylation
(Fig. 4A, lanes 1–2). This effect was blunted by treating cells with
wortmannin (Fig. 4A, lanes 3–4), indicating the effect is mediated
by PI3K, analogous to the results we obtained in wing discs. Since
one important mediator of PI3K function is the kinase PDK1
(Fig. 7G), we asked whether PDK1 is necessary for insulin to
regulate Yki. Indeed, knocking down PDK1 with two independent
non-overlapping dsRNAs abolished the ability of insulin to affect
Yki phosphorylation (Fig. 4B). In the insulin signaling cascade,
PDK1 activates Akt/PKB. In addition, in mammals PDK1 also
activates aPKC (Scott et al., 2002; White, 2003), however it is
unclear whether this is also the case in Drosophila. Recently,
Drosophila aPKC was reported to affect Hippo localization and
activity (Grzeschik et al., 2010). We therefore asked whether PI3K
regulates Yki via aPKC. Western blot analysis of wing discs
expressing Dp110-CAAX revealed no increase in autophosphor-
ylation of aPKC, a marker for aPKC activity (Wirtz-Peitz et al.,
2008) (Supplemental Fig. 2), suggesting PI3K does not regulate
Yki via aPKC. We then asked whether the other PDK1 target, Akt,
is able to affect Yki activity. Overexpression of Akt in the posterior
compartment of the wing disc caused a very mild but consistent
increase in diap-lacZ expression which is rendered more obvious
Fig. 2. Insulin signaling affects Yki activity in Drosophila. (A–A0) Overexpression of PI3K (nub4Dp110-CAAX) increases Drosophila wing size due to enhanced cell
proliferation, whereas overexpression of Rheb (nub4Rheb) results in larger wings due to increased cell growth. (A) Representative wings of indicated genotypes kept at
25 1C. (A0) Quantiﬁcation of wing size and cell size (quantiﬁed via hair density) for ten wings of each genotype shown in A. Error bars: standard deviation (SD);
* t testo0.001 relative to control wings. (B) Overexpression of Dp110-CAAX, but not Rheb, decreases Yki phosphorylation in Drosophila wing imaginal discs. Dp110-CAAX
or Rheb were overexpressed with nubbin-Gal4 at 25 1C and wing disc lysates from wandering 3rd-instar larvae were analysed by immunoblotting with indicated
antibodies. (C) Inhibition of endogenous PI3K activity increases Yki phosphorylation in Drosophila Cl8þ cells. Lysates of cells treated with either vehicle (DMSO) or 800 nM
wortmannin for 1 hour were analysed by immunoblotting with indicated antibodies. (D–E) PI3K regulates Yki transcriptional activity in Drosophila wing imaginal discs.
(D) Quantitative RT-PCR on Yki targets merlin, expanded and cyclin E, on control discs and discs overexpressing Dp110-CAAX, normalized to rp49. Error bars SD.
*t testo2103. (E) Expression of Yki target gene diap1 is regulated by PI3K activity in vivo. Diap1 expression, revealed via diap-lacZ reporter staining, in control wing
discs (enG4), or discs speciﬁcally expressing in the posterior (P) compartment constitutively active PI3K (en4UAS-myc-Dp110-CAAX) or dominant-negative PI3K
(en4UAS-myc-Dp110 DN). Staining anti-myc-tag indicates the expression domain. Scale bar¼50 mm.
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Since the effect of Akt expression on the diap-lacZ reporter was
mild in comparison to the effect of PI3K, we tested whether IISmight be affecting Yki mainly via an Akt-independent manner.
Indeed, knockdown of Akt in S2Rþ cells did not completely
abolish the effect of insulin on Yki phosphorylation (not shown
K. Straßburger et al. / Developmental Biology 367 (2012) 187–196 191– see below), suggesting IIS can also affect Yki signaling via an
Akt-independent mechanism. Recently, the LIM-domain protein
dJub was reported to regulate Hpo signaling (Das Thakur et al.,
2010) and to bind PI3K (Glatter et al., 2011), providing a possible
Akt-independent link between IIS and Yki. However, knockdown
of dJub, or simultaneous knockdown of dJub and Akt did not
abolish the ability of insulin to affect Yki phosphorylation
(Fig. 4D). Therefore, there appears to be an additional PDK1 target
which, together with Akt, links IIS to Hippo signaling.IIS regulates Yorkie activity via Hippo
Yki is phosphorylated on S168 by the kinase Wts (Dong et al.,
2007; Huang et al., 2005). Therefore, reduced Yki S168 phosphoryla-
tion upon increased insulin signaling (Fig. 2B) suggests Wts activity isFig. 4. Insulin signaling activates Yki via Akt. (A) Insulin causes reduced phosphorylatio
human insulin (10 mg/mL) in the presence or absence of wortmannin (500 nM), lyse
reduced phosphorylation of Yki in a PDK1-dependent manner. S2Rþ cells were treated
PDK1 for 5 days, then stimulated with 10 mg/mL insulin for 60 min, lysed, and assayed b
transcriptional target Diap1. Expression of Akt in the posterior compartment using
compared to control discs (en4þ). Intensity proﬁles, averaged over the entire ven
bar¼50 mm. (D) Removal of dJub or both dJub and Akt combined does not ablate the
dsRNAs targeting dJub or Akt. Knockdown of Akt was highly efﬁcient, judged by comp
Fig. 3. Insulin signaling affects YAP phosphorylation in mammalian cells. Mouse
NIH-3T3 ﬁbroblasts (A) or human HeLa cells (B) were treated 7800 nM wort-
mannin (A) or 100 nM wortmannin (B) for one hour and cell lysates were analysed
by immunoblotting with indicated antibodies.reduced under these conditions. The activity of Wts is positively
regulated in part via phosphorylation on T1077 by Hippo (Reddy and
Irvine, 2008; Yu et al., 2010). We asked whether Wts phosphorylation
is affected by Dp110-CAAX, and found that this is indeed the case.
Discs expressing Dp110-CAAX had reduced levels of Wts phosphor-
ylation on T1077 compared to controls (Fig. 2B). Wts is phosphory-
lated on T1077 by the kinase Hpo, suggesting that IIS regulates, either
directly or indirectly, Hpo activity. We set out to test this genetically
via epistasis experiments. As a control, we ﬁrst tested whether
Dp110-CAAX drives cells proliferation via an upstream component
of the Hpo signaling pathway, expanded. MARCM clones expressing
Dp110-CAAX but lacking expanded were signiﬁcantly overgrown
compared to MARCM clones lacking expanded (Fig. 5A, Supplemental
Fig. 3A), indicating that Dp110-CAAX does not require expanded to
drive proliferation. This also suggests that the signaling input from IIS
to Yki occurs somewhere downstream or in parallel to expanded. We
next asked whether Dp110-CAAX drives cell proliferation via repres-
sion of Hpo. MARCM clones either lacking Hpo or expressing Dp110-
CAAX signiﬁcantly overgrow compared to controls (Fig. 5B). This
could be quantiﬁed by measuring total clone area per disc for these
genotypes (Fig. 5B0). As often observed, the biological variability in
clone size is large. Nonetheless, there is a clear 42-fold increase in
the size of Dp110-CAAX clones compared to control clones, and this
increase is statistically signiﬁcant (Fig. 5B0). In contrast, MARCM
clones simultaneously lacking Hpo and overexpressing Dp110-CAAX
did not overgrow compared to MARCM clones lacking Hpo only
(Fig. 5B, B0). The samewas observed if the area of the largest clone per
disc for each genotype was quantiﬁed (Supplemental Fig. 3B). This
indicates that insulin signaling regulates Yki signaling at the level of
Hpo or above. Surprisingly, this also indicates that PI3K is not able to
induce proliferation in a Hpo mutant background. This suggests that
Hippo/Yki signaling is an important effector mechanism by which IIS
drives proliferation.n of Yki in a PI3K dependent manner in S2Rþ cells. Cells were treated for 1 h with
d, and assayed by immunoblotting with indicated antibodies. (B) Insulin causes
with control (GFP) dsRNA or two independent non-overlapping dsRNAs targeting
y immunoblotting with indicated antibodies. (C) Akt induces expression of the Yki
engrailed-GAL4 (en4Akt) causes elevated expression of the diap-lacZ reporter,
tral pouch (shown as white boxes), are indicated below the micrographs. Scale
effect of insulin on Yki phosphorylation. Cells were treated as in (B), except with
lete depletion of Akt protein (4th panel from the top).
Fig. 5. Insulin signaling regulates Yki at the level of Hpo or above. (A) Hpo
upstream regulator Expanded is not required for PI3K induced overgrowth. GFP-
marked MARCM clones expressing activated PI3K and lacking expanded (exe1)
(ex-; Dp110-CAAX) overgrow compared to MARCM clones lacking expanded. Scale
bar¼50 mm. (B–B0) PI3K cannot further increase the growth rate of Hpo mutant
cells. GFP-tagged MARCM clones either lacking Hpo (hpokc202) or expressing
activated PI3K (Dp110-CAAX) overgrow compared to control MARCM clones.
Expression of PI3K does not further increase the size of Hpo mutant clones (hpo;
Dp110-CAAX). Representative discs (B) and quantiﬁcation of total clone area per
disc (B0). Error bars represent standard deviation. * t testo0.03. Scale bar¼50 mm.
Fig. 6. Insulin signaling requires Yki activity to promote cell proliferation.
(A) PI3K-induced overgrowth requires Yki. GFP-labeled MARCM clones over-
expressing constitutively active PI3K (Dp110-CAAX) overgrow compared to
control MARCM clones (WT), but not in the absence of Yorkie (Yki versus Yki-;
Dp110-CAAX). Scale bar¼50 mm. (B) PI3K-induced overgrowth is sensitive to Yki
gene dosage. Animals expressing constitutively active PI3K in the wing pouch with
nubbin-GAL4 (nubG44Dp110-CAAX) at 21 1C have signiﬁcantly increased wing
size compared to controls (nubG4). Removal of one copy of Yorkie (YkiB5/þ ,
‘‘Ykiþ/ ’’) signiﬁcantly blunts this overgrowth. Error bars: SD. **t testo0.01,
***t test¼1011.
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We next tested whether IIS requires Yki signaling to drive cell
proliferation. We ﬁrst performed a genetic epistasis experiment,
testing whether PI3K is able to induce cell proliferation in the
absence of Yki. As a control, we generated in the wing disc
MARCM clones expressing Dp110-CAAX, and found that they
strongly overgrow compared to control MARCM clones, as
expected (Fig. 6A). This difference was clearly visible in both
2-days-old and 3-days-old clones (Fig. 6A). In contrast, MARCM
clones simultaneously expressing Dp110-CAAX and lacking Yki
did not overgrow compared to Yki mutant clones (Fig. 6A,
Supplemental Fig. 4) indicating that in the absence of Yki,
Dp110-CAAX is not able to promote cell growth and proliferation.
We next performed a sensitive genetic interaction test to see
whether the overgrowth caused by Dp110-CAAX is sensitive to
Yki gene dosage. Animals expressing Dp110-CAAX with nubbin-
GAL4 in the wing blade were grown under controlled density
conditions, and compared to nubbin-GAL4 control animals. As
expected, Dp110-CAAX-expressing animals had wing blades of
signiﬁcantly increased size (Fig. 6B). Removing one copy of Yki in
the wildtype background did not reduce total wing size (Fig. 6B).However, removing one copy of Yki in animals overexpressing
Dp110-CAAX signiﬁcantly blunted the ability of Dp110-CAAX to
cause tissue overgrowth (Fig. 6B). This indicates that the ability of
Dp110-CAAX to promote tissue growth is very sensitive to Yki
gene dosage, suggesting that activation of Yki plays an important
and limiting role in the ability of PI3K to drive tissue growth.
The Hippo/Yorkie pathway regulates TOR activity
Our initial observations suggested that activation of IIS and Yki
signaling correlate in hepatocellular carcinoma, and the above-
mentioned experiments analyzed whether IIS activates Yki. We
also asked the converse – whether Hpo/Yki signaling affects IIS.
To this end, we performed western blot analysis on dissected
wtsP2 mutant wing discs, which are signiﬁcantly overgrown due
to lack of warts protein and hyperactivation of Yki (Justice et al.,
1995). Surprisingly, wtsP2 mutant discs have signiﬁcantly ele-
vated levels of S6K phosphorylation compared to controls
(Fig. 7A), suggesting that not only does IIS affect Yki activation,
but that perhaps Yki also affects IIS. Indeed, expression of
Yki[S168A], an activated form of Yki (Dong et al., 2007), speciﬁ-
cally in wing discs also caused a signiﬁcant increase in S6K
phosphorylation compared to controls (Fig. 7B). Since Yki is a
transcriptional regulator, we tested by quantitative RT-PCR
whether modulation of Hpo/Yki signaling causes a change in
expression of any known components of the insulin pathway.
Indeed, expression of the negative regulators Tsc1, Tsc2, PTEN and
USH were all down-regulated in wing discs homozygous for the
wtsP2 mutation (Fig. 7C) or in wing discs expressing activated Yki
Fig. 7. Yorkie signaling activates insulin/IGF signaling. (A–B) Yki activation, either via mutation of warts (A) or via wing-disc speciﬁc expression of activated Yki (B), causes
hyperphosphorylation of S6K. Wing disc lysates from wandering 3rd-instar larvae of indicated genotypes were analysed by immunoblotting. (C–E) Yki activation causes
transcriptional changes in genes encoding components of the IIS pathway. Quantitative RT-PCR, normalized to rp49, was performed on RNA extracted from isolated wing
discs of indicated genotypes. (F) An 85nt region from the Insulin Receptor (InR) 1st intron is transcriptionally responsive to Yki. S2Rþ cells were transfected with a
negative-control ﬁreﬂy luciferase reporter (empty control), or the same reporter containing either a positive-control Hippo Responsive Element (HRE, (Wu et al., 2008)) or
the 85 nt region from InR (InR-reporter). Reporter activity, normalized to a renilla-luciferase control, is indicated 18 h after induction of either Scalloped (Sd) or
ScallopedþYki (SdþYki). (G) Schematic diagram illustrating the interconnections between the IIS and Hpo/Yki pathways. IIS activates Yki via Akt as well as via a second
target of PDK1. Yki activation causes transcriptional changes in multiple genes encoding components of the IIS pathway. The IIS/TOR signaling pathway contains a well-
established negative feedback loop between S6K and activation of PI3K.
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marked increase in expression of insulin receptor (InR) and PDK1
(Fig. 7E). These results are in agreement with recent ﬁndings in
rat cardiomyocytes suggesting this regulatory connection
between Yki and IIS is ancestral and evolutionarily conserved
(Xin et al., 2011). To test whether some of these effects might be
direct, we scanned the InR genomic region for Yki/Sd binding sites
(CATTCCA) (Wu et al., 2008) using Genome Enhancer software
(Markstein et al., 2002). Surprisingly, we found two such sites
clustered within an 85-nt region in the ﬁrst intron of InR. When
placed upstream of luciferase containing a basal promoter, this
region caused the reporter to become Yki responsive (Fig. 7F).Discussion
This study provides evidence that the insulin/IGF signaling
(IIS) pathway and the Hpo/Yki signaling pathway are intricately
interlinked in normal development and in cancer. In addition to
observing a correlation in activation of the two pathways in
hepatocellular carcinoma, our mechanistic studies suggest that
IIS activates Yki signaling and vice-versa (Fig. 7G). IIS appears to
activate Yki via two mechanisms, a minor one involving Akt and a
second major one via another target of PDK1 (Fig. 4). Both appear
to function via Hpo repression (Fig. 5). A previous report found
that Akt can phosphorylate and inactivate MST1 in HeLa cells in
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tested whether a direct phosphorylation of Hpo by Akt might
explain the growth effects we observe. We could not observe,
however, an Akt-mediated phosphorylation of Hpo neither by
in vitro kinase assay nor by isoelectric focusing of cell extracts
treated in the presence or absence of insulin (not shown).
Furthermore, by expressing phospho-mimetic or alanine mutant
versions of Hpo in vivo in the ﬂy, we could not observe an effect
on Hpo activity. In sum, we could not ﬁnd data supporting the
idea that the growth-promoting effect of IIS occurs via direct
phosphorylation of Hpo by Akt, in agreement with our ﬁnding
that the major mechanism by which IIS affects Yki is Akt-
independent (Fig. 4). In addition, a previous report found that
Akt might also directly phosphorylate and inhibit YAP (Basu et al.,
2003), which is surprising given that both Akt and YAP have
similar – and not antagonistic – effects on cell growth and
proliferation. A subsequent study was not able to conﬁrm this
ﬁnding (Zhao et al., 2007) leaving this an open issue. Likewise, the
connections from Yki to IIS appear to be multiple, as we see
transcriptional regulation of a large number of components of the
IIS pathway upon Yki activation (Fig. 7). These interconnections
lead to coordinated activation of the two pathways.
Our main ﬁnding is that insulin/IGF signaling drives prolifera-
tion partly via Hpo/Yki signaling. We ﬁnd that IIS regulates Yki
activity in vivo, both at the biochemical level (Fig. 2B and C), and
in terms of Yki transcriptional activity (Fig. 2D and E). Although
analysis of Yki phosphorylation and of four Yki targets (DIAP1,
merlin, expanded and cyclin E) consistently indicate that IIS
activates Yki (Fig. 2), surprisingly we do not see an increase in
expression of another yorkie target, bantam, upon expression of
Dp110-CAAX, consistent with previous ﬁndings (Thompson and
Cohen, 2006). Since bantam is an outlier compared to all other
yorkie targets we tested, this likely suggests bantam has other
transcriptional regulatory inputs. Since the growth caused by
Dp110-CAAX expression is abrogated in the absence of Hpo
(Fig. 5B and B0) and highly sensitive to Yki gene dosage
(Fig. 6B), this indicates that Yki is an important and limiting
effector mechanism by which IIS drives tissue growth. Since the
regulation of Yki/YAP by IIS is conserved from ﬂies to humans,
this mechanism likely represents an ancestral mechanism by
which IIS drives tissue growth.
Hpo appears to be a central hub for integrating numerous inputs
that affect tissue growth. The overgrowth caused by removal of
upstream regulators of Hpo, such as Merlin, Expanded, Fat, Dachsous,
Dco, Kibra and Crumbs, are mild in comparison to the overgrowth
caused by loss of Hpo, suggesting these upstream components
function in a combinatorial and additive manner to regulate Hpo
(Pan, 2010). The work described here provides an additional input
into Hpo signaling. Since IIS is responsive to nutrient conditions in
addition to growth factor signaling, this links nutrient status to Hpo/
Yki signaling and animal growth. It is tempting to speculate that
nutrient overload and hyperactivation of the IIS pathway over an
extended time in an adult organism might, via this mechanism,
potentially contribute towards hyperplasia.
Recently, the YAP signaling pathway was found to be linked
to several other oncogenic pathways including TGF-beta, beta-
catenin and EGF signaling (Ferrigno et al., 2002; Heallen et al.,
2011; Zhang et al., 2009). In each case, however, the link is that
YAP affects signaling through the other pathway. For instance,
YAP interacts with b-catenin to regulate a subset of Wnt target
genes (Heallen et al., 2011), and YAP upregulates expression of
the EGFR ligand amphiregulin to activate EGF signaling (Zhang
et al., 2009). To our knowledge, the ﬁndings presented here are
the ﬁrst in which the link also goes in the other direction, with IIS
regulating Hpo and Yki signaling, thereby adding growth factor
signaling as an input into Hpo/Yki.Thus far, Yki has been found to regulate expression of genes
affecting mainly cell proliferation (e.g. CycE) and apoptosis (e.g.
diap1). The data presented here suggest a mechanism by which
Yki can induce tissue growth by also affecting TOR activity, thus
activating both cell proliferation and cell growth in Drosophila.
This further extends and is in line with recently published data
that show that YAP overexpression can drive IIS in mouse
cardiomyocytes (Xin et al., 2011).
In sum, the data presented here reveal one molecular mechanism
by which IIS drives proliferation, they identify a novel input into
Hpo signaling, and they elucidate cross-talk between two estab-
lished oncogenic pathways of relevance for cancer development.Methods
Constructs and ﬂy strains
Fly lines were obtained from the following sources: nubbin-
GAL4, UAS-Dp110-CAAX, UAS-Dp110-DN, UAS-Rheb (Bloomington
Stock Center); diap-lacZ (Huang et al., 2005); exe1 (Boedigheimer
and Laughon, 1993); Hpokc202 were a kind gift from G Halder (Udan
et al., 2003).
Antibodies
Antibodies were obtained from the following sources: anti-
phospho Akt substrate (Cell Signaling #9611); anti-phospho-
Akt(Ser505) (Cell Signaling #4054); anti-phospho Akt(T308) (Cell
Signaling #2965); anti-Akt (Cell Signaling #9272); anti-phospho-
S6K(Thr389) (Cell Signaling, #9234); anti-myc-tag (Cell Signaling
#2278); anti-phospho-YAP (Cell Signaling #4911); anti-total YAP
(Cell Signaling #4912); anti-S6K (Hahn et al., 2010); anti-Tubulin
and anti-beta-gal (Developmental Studies Hybridoma Bank clones
AA4.3 and 40-1A); anti-phospho PKC iota (T555þT563) (Abcam);
anti-phospho-Yorkie was a kind gift from DJ Pan (Huang et al.,
2005) as well as Nic Tapon (Genevet et al., 2010), anti-total Yorkie
and anti-phospho-wts were kind gifts from DJ Pan (Huang et al.,
2005);
Quantitative RT-PCR
RNA was extracted using Trizol (Invitrogen), and reverse-
transcribed with SuperScript III (Invitrogen). Q-PCR was per-
formed using Maxima SYBR Green/ROX (Fermentas), normalized
to rp49. Oligo sequences can be provided upon request.
Immunoblotting and antibody tissue staining
Both immunoblotting and immunoﬂuorescent stainings of
tissues were performed as previously described (Hahn et al.,
2010). Fig. 4B and D were obtained using a Licor OdysseyFc
scanner, and were quantiﬁed using the Licor software suite.
Figs. 2C, 3A, 3B and 4A were obtained by exposing ﬁlm and were
quantiﬁed using ImageJ (integrated density minus background).
HCC tissue microarrays
Tissue microarray production, staining procedure, signal eva-
luation, and statistical data analysis were performed as previously
described (Singer et al., 2007). YAP and pAkt staining were each
scored twice independently by two pathologists yielding similar
results. Since YAP expression is not homogenous in tumor
samples, a score was obtained by multiplying the number of
positive tumor cells (score range from 0 to 4) and the YAP staining
intensity (score range from 0 to 3). pAkt staining was more
K. Straßburger et al. / Developmental Biology 367 (2012) 187–196 195homogenous within the samples and scored on a range from 0–3.
Similar correlations were also observed with computer-aided
automated image quantiﬁcation.
Luciferase assay
For the InR reporter, an 85-nt region from the 1st intron of InR
was ampliﬁed by PCR (oligos ggccgagctcAAGCTCCACATTGT-
TAAAAAA and ggccacgcgtATCGCAAGCAGAATAAAGC) and cloned
upstream of ﬁreﬂy luciferase containing an Adh basal promoter. A
positive-control Hippo Responsive Element (HRE, (Wu et al.,
2008)) was likewise cloned by oligo-cloning. Fireﬂy luciferase
reporters, together with a renilla normalization control plasmid,
were transfected into S2Rþ cells together with pMT-Sd in the
presence or absence of pMT-Yki, and Sd and Yki expression were
induced by copper addition.Acknowledgments
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